STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by STAT News; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Newseze's algorithm reads the story and answers your question — calmly, factually, with source attribution. No comments, no flame wars — just answers.
No questions yet. Be the first.
Answers reflect Newseze's editorial framework applied under fair use (17 U.S.C. § 107). Not financial, legal, medical, or tax advice. Hate speech and racial slurs are blocked.
Related stories
Why it mattersTwo newly elected lawmakers with science backgrounds hope to push back against Trump administration cuts to health equity programs.
By Chella·18h ago
Why it mattersDemocrats are likely to focus on reversing Medicaid cuts and expanding insurance coverage, giving a boost to health care providers.
By Chella·22h ago
Why it mattersCalley Means, a MAHA leader who just resigned from the Trump administration, says Americans "are being duped and gaslighted and lied to."
By Chella·18h ago
Why it mattersThe Trump administration is facing another lawsuit over its sweeping changes to Medicaid less than a week after a federal judge ruled that implementation of work requirements would cause “irreparable…
By Chella·18h ago